| capecitabine / Generic mfg. |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 08/22 | 02/24 | | |
2022-000273-81: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy |
|
|
| Not yet recruiting | 2 | 118 | Europe | LONSURF, ELVORINE, Coated tablet, Solution for infusion, Capsule, LONSURF, ELOXATINE, FOLINATE DE CALCIUM, 5-Fluorouracil, capecitabine, ELVORINE | UNICANCER, Laboratoire SERVIER | Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy., Oxaliplatin in combination with trifluridine/tipiracil or 5-fluorouracile in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04472143: Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents |
|
|
| Recruiting | 2 | 60 | RoW | Granisetron Transdermal Delivery System, sancuso; granisetron transdermal patch | Fudan University | Chemotherapy-induced Nausea and Vomiting (CINV) | 09/22 | 12/22 | | |
SUNRISE, NCT03714490: MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer |
|
|
| Recruiting | 2 | 200 | RoW | SCPRT, CRT, CAPOX, capecitabine, oxaliplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rectal Neoplasms | 09/24 | 09/25 | | |
NCT04119622: Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, oxaliplatin, capecitabine | Aiping Zhou | Gastric Cancer Stage II, Gastric Cancer Stage III | 09/22 | 10/24 | | |
| Recruiting | 2 | 104 | RoW | AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil | Akeso | Metastatic Colorectal Cancer | 12/24 | 12/26 | | |
RETICULA-NPC, NCT04921995: Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab | Fudan University | Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy, Stereotactic Body Radiation Therapy (SBRT) | 10/22 | 06/24 | | |
| Completed | 2 | 180 | Europe | XELOX, Radiotherapy | Niguarda Hospital | Colo-rectal Cancer | 10/22 | 12/22 | | |
NCT02978612: Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III |
|
|
| Active, not recruiting | 2 | 170 | Europe | Capecitabine, Xeloda | Oslo University Hospital | Colon Cancer | 11/22 | 01/32 | | |
2022-000776-19: Master Protocol of Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours Protocolo Maestro de Dato-DXd en Monoterapia y en Combinación con Agentes Antineoplásicos en Pacientes con Tumores Sólidos en Estadio Avanzado o Metastásico |
|
|
| Not yet recruiting | 2 | 670 | Europe | AZD5305, Durvalumab, Datopotamab deruxtecan, Capecitabine, Flourouracil (5-FU), Bevacizumab, Carboplatin, leucovorin, Nivolumab, AZD5305, MEDI4736, DS-1062a, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Solution for injection, MVASI, Prednisolone | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | Various Advanced/Metastatic solid tumour types- Endometrial Cancer - Gastric Cancer - Ovarian Cancer- Metastatic castration-resistant prostate cancer- Colorectal cancer Varios tipos de tumores sólidos avanzados/metastásicos- Cáncer endometrial- Cáncer gástrico- Cáncer de ovario- Cáncer de próstata metastásico resistente a la castración- Cáncer colorrectal, Metastatic Cancer, Multiple cancers Cáncer metastásico, Múltiples cánceres, Diseases [C] - Cancer [C04] | | | | |
NCT04034251: Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis |
|
|
| Active, not recruiting | 2 | 12 | US | Paclitaxel, Taxol, Capecitabine, Xeloda, BardPort Titanium Implanted Port with Peritoneal Catheter | National Cancer Institute (NCI) | Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis | 02/23 | 01/27 | | |
PANDORA, NCT04083365: Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer |
|
|
| Recruiting | 2 | 100 | Europe | Capecitabine, Radiotherapy, Durvalumab | AUSL Romagna Rimini, AstraZeneca, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | RECTAL CANCER | 11/22 | 08/25 | | |
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable | 11/22 | 12/23 | | |
| Active, not recruiting | 2 | 1460 | Europe | AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736 | UNICANCER, Fondation ARC, AstraZeneca | Metastatic Breast Cancer | 12/22 | 12/24 | | |
| Active, not recruiting | 2 | 200 | US | Capecitabine, Xeloda® | Qamar Khan | Breast Cancer, Gastrointestinal Cancer | 12/22 | 12/23 | | |
| Completed | 2 | 140 | Europe | Paclitaxel, Paclitaxel Sandoz, Cyclophosphamide, Endoxan Baxter, Capecitabine, Xeloda, Vinorelbine, Navelbine | ETOP IBCSG Partners Foundation | Breast Cancer | 11/21 | 11/22 | | |
NCT04246502: Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 200 | NA | Capecitabine and Pyrotinib, Capecitabine,Trastuzumab, and Pertuzumab | Shandong Cancer Hospital and Institute | Metastatic Breast Cancer | 12/22 | 12/24 | | |
NCT04249739: Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive |
|
|
| Active, not recruiting | 2 | 93 | RoW | Pembrolizumab, Keytruda, MK3475 | Samsung Medical Center | Gastric Cancer | 02/24 | 03/25 | | |
NCT04663763: Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | PD-1 antibody, Sintilimab, Capecitabine, Oxaliplatin | Zhejiang Cancer Hospital | Locally Advanced Rectal Cancer | 12/22 | 12/25 | | |
ChiCTR2000037206: Efficacy and safety of intensive adjuvant treatment with a CDK4/6 inhibitor in non-pCR patients with HR-positive HER2-negative breast cancer after neoadjuvant chemotherapy: a prospective, multicenter, randomized, open-label phase II clinical study |
|
|
| Not yet recruiting | 2 | 283 | | standard endocrine + palbociclib 1 year ;Standard endocrine therapy for 1 year+Capecitabine 1000 mg/m2, bid D1-D14 | Changhai Hospital, Navy Medical University, Shanghai; Changhai Hospital, Navy Medical University, Changhai Hospital, Navy Medical University, Shanghai, People's Republic of China. | Breast Cancer | | | | |
NCT04664504: A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk |
|
|
| Recruiting | 2 | 150 | RoW | Concurrent Chemoradiotherapy Radiotherapy, CRT, Short-course Radiotherapy, SCRT, Local dose increase of Short-course Radiotherapy, es-SCRT, Consolidation chemotherapy, XEOLX*4 courses, Adjuvant chemotherapy, XEOLX*6 courses, TME | Jing Jin, M.D. | Rectal Cancer | 12/22 | 12/25 | | |
NCT04911517: Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC. |
|
|
| Recruiting | 2 | 50 | RoW | long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations | Beijing Friendship Hospital, Hangzhou New Horizon Health Technology Co., Ltd., Beigene (Beijing) Biotechnology Co., Ltd, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Tianjin Medical University General Hospital, People's Hospital of Tianjin, Tianjin Medical University Cancer Institute & Hospital | Colorectal Neoplasms | 12/22 | 12/24 | | |
ALTER-G-001, NCT05262335: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis |
|
|
| Recruiting | 2 | 116 | RoW | Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastrointestinal Tumors | 12/23 | 12/24 | | |
NCT05254847: Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC |
|
|
| Recruiting | 2 | 75 | RoW | Capecitabine combined with lenvatinib and tislelizumab | Fudan University | Biliary Tract Cancer | 12/22 | 12/24 | | |
NCT05545436: Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 34 | RoW | Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ), Camrelizumab + SOX / XELOX | Third Affiliated Hospital, Sun Yat-Sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Locally Advanced Gastric Cancer | 12/22 | 06/23 | | |
NCT06417476: Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer |
|
|
| Recruiting | 2 | 66 | RoW | Short-course radiotherapy, Irinotecan, Oxaliplatin, Calcium Formate, Fluorouracil, Long-course chemoradiation, Capecitabine | Pei-Rong Ding, Yunnan Cancer Hospital, Liaoning Tumor Hospital & Institute, Shantou Central Hospital, Fujian Cancer Hospital, Jiangsu Provincial People's Hospital | Rectal Neoplasms | 12/24 | 12/25 | | |
NCT01972919: Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 23 | US | Radiation Therapy, Dose escalation radiation therapy, Concurrent chemotherapy (Gemcitabine, Capecitabine), Gemzar, Xeloda | Medical College of Wisconsin | Unresectable Pancreatic Cancer | 12/23 | 12/24 | | |
| Active, not recruiting | 2 | 171 | Europe, RoW | Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab, gastrectomy | European Organisation for Research and Treatment of Cancer - EORTC | Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression | 12/22 | 12/28 | | |
NCT04856761: A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection |
|
|
| Recruiting | 2 | 160 | RoW | S-1, Tegafur, Capecitabine, XELODA | Fudan University | Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma, Gall Bladder Cancer | 12/22 | 12/24 | | |
NCT04780347: Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer |
|
|
| Recruiting | 2 | 92 | RoW | Albumin-bound paclitaxel plus capecitabine, capecitabine | Fudan University | Breast Cancer | 12/22 | 02/23 | | |
ChiCTR2000029807: Combination of Camrelizumab and Neoadjuvant Chemotherapy in Esophageal Cancer |
|
|
| Recruiting | 2 | 47 | | All patients will receive 3 cycles of camrelizumab (200mg, on days 1), concurrently with 3 cycles of Albumin paclitaxel/capecitabine (Albumin paclitaxel 260mg/m2, on days 1; capecitabine 1250mg/m2, on days 1-14). Esophagectomy is performed 6-8 weeks after neoadjuvant therapy completion | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Business funding (Jiangsu Hengrui Pharmaceutical Limited Company, Shiyao Holding Group Limited Company) | Esophageal squamous cell carcinoma | | | | |
NCC2167, NCT04389073: Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine |
|
|
| Recruiting | 2 | 138 | RoW | Vinorelbine 40mg, Toripalimab 240mg, JS001, Bevacizumab 5 mg/kg, Cyclophosphamide 50 mg, Capecitabine 500Mg Oral Tablet, Cisplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Huanxing Cancer Hospital | Metastatic Breast Cancer | 12/22 | 12/23 | | |
ChiCTR2000032317: Efficacy and safety of induction chemotherapy of albumin-bound paclitaxel, cisplatin and capecitabine and sequential concurrent chemoradiotherapy combined with apatinib and camrelizumab for stage N3M0 nasopharyngeal carcinoma: a prospective, single-arm, open labeled phase II clinical trial |
|
|
| Completed | 2 | 50 | | induction chemotherapy of albumin-bound paclitaxel, cisplatin and capecitabine and sequential concurrent chemoradiotherapy combined with apatinib and camrelizumab | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | | | | |
ChiCTR2000040318: The safety and efficacy of Sindili in the perioperative treatment of locally advanced rectal cancer: single-arm, single-center study |
|
|
| Not yet recruiting | 2 | 35 | | Sintilimab + Radiation therapy + Oxaliplatin + capecitabine | Xuzhou Central Hospital; Xuzhou Central Hospital, self-financing | rectal cancer | | | | |
ChiCTR2100041919: Initumab combined with chemotherapy or pyrrotinib in the treatment of HER2+ advanced gastric and gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 2 | 50 | | Initomab combined with XELOX ;Initolumab combined with pyrrotinib + paclitaxel | The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University, China Anti-cancer Association | Gastric cancer | | | | |
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Fudan University | Triple Negative Breast Cancer | 01/23 | 01/23 | | |
NCT04733963: Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 112 | RoW | Fruquintinib Plus Capecitabine, Bevacizumab Plus Capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 01/23 | 02/23 | | |
ChiCTR2100051884: Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor secondary prophylaxis in capecitabine combined with oxaliplatin (CapeOX) regimen in the treatment of colorectal cancer |
|
|
| Not yet recruiting | 2 | 20 | | The test drug PEG-rhG-CSF injection was administered 24-48 hours after the end of oxaliplatin intravenous infusion | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | Colorectal cancer | | | | |
NCT01494662: HKI-272 for HER2-Positive Breast Cancer and Brain Metastases |
|
|
| Active, not recruiting | 2 | 140 | US | HKI-272, Neratinib, Surgical Resection, Biopsy, Capecitabine, Xeloda, Ado-Trastuzumab Emtansine, T-DM1 | Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc. | Breast Cancer | 02/23 | 12/24 | | |
|
|
|
|
|
|
|
| Completed | 2 | 36 | US | Oxaliplatin+Capecitabine+Pembrolizumab | Duke University, Merck Sharp & Dohme LLC | Gastric Cancer, Esophagus Cancer | 02/23 | 02/23 | | |
NCT04894123: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients |
|
|
| Terminated | 2 | 1 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin | GERCOR - Multidisciplinary Oncology Cooperative Group, Servier | Colorectal Adenocarcinoma, Oesogastric | 02/23 | 02/23 | | |
2018-003112-53: Predictive value of analyzing cancer cells from patients with pancreatic cancer for possible effect of different anti-cancer drugs |
|
|
| Not yet recruiting | 2 | 30 | Europe | Oxaliplatin, Capecitabine, Irinotecan, 5-FU, Gemcitabine, Nab-paclitaxel, Erlotinib, Cisplatin, Docetaxel, Olaparib, Solvent for solution for infusion, Tablet, Concentrate and solvent for concentrate for solution for infusion, Concentrate for dispersion for infusion, Concentrate and solvent for solution for infusion, Powder for solution for infusion, Concentrate for solution for infusion | Vejle Hospital | Pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 37 | RoW | Avelumab, MSB0010718C, 5 Fluorouracil, Capecitabine Pill, Radiotherapy, Surgical Resection | Peter MacCallum Cancer Centre, Australia | Rectal Cancer | 02/23 | 02/23 | | |
ChiCTR2100049647: The clinical study of camrelizumab combined with CAPEOX regimen in the first-line treatment of advanced colorectal cancer |
|
|
| Not yet recruiting | 2 | 100 | | Carrelizumab + capecitabine + oxaliplatin | The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Colorectal cancer | | | | |
COBP, NCT05585814: Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 12 | NA | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Shanghai Changzheng Hospital | Locally Advanced Colorectal Cancer | 03/23 | 10/25 | | |
NCT05588297: Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | 2 | 12 | NA | CapOx(Capecitabine+ Oxaliplatin), Bevacizumab, Nivolumab | Shanghai Changzheng Hospital | Colorectal Cancer Liver Metastases | 03/23 | 10/25 | | |
BACCI, NCT02873195: Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 133 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Capecitabine, Ro 09-1978/000, Xeloda, Laboratory Biomarker Analysis, Placebo, placebo therapy, PLCB, sham therapy | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7 | 03/23 | 07/24 | | |
ChiCTR2200057850: Efficacy and safety of xindilimab combined with oxaliplatin / capecitabine (XELOX) in neoadjuvant therapy of locally advanced gastric cancer: a prospective, single center, phase II study |
|
|
| Not yet recruiting | 2 | 46 | | Cindilimab combined with XELOX regimen | Henan Provincial People's Hospital; Henan Provincial People's Hospital, The cost of continuous blood glucose test and ambulatory electrocardiogram in this study shall be paid by themselves according to the hospitalization charging process; However, the cost of subsequent | Gastric cancer | | | | |
NCT05291052: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, Lenvatinib, Oxaliplatin, Capecitabine | The First Affiliated Hospital with Nanjing Medical University | Biliary Tract Tumor | 03/23 | 03/24 | | |
NCT04309578: A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC |
|
|
| Recruiting | 2 | 28 | RoW | Trastuzumab, Capecitabine and Cisplatin | Asan Medical Center | Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma | 12/24 | 12/24 | | |
PRECAM, NCT05216653: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 32 | RoW | Envafolimab, KN053, Oxaliplatin, Capecitabine, Short-course Radiation, TME surgery, total mesorectal excision | Sir Run Run Shaw Hospital | MSS Locally Advanced Rectal Adenocarcinoma | 03/23 | 03/25 | | |
EXPLORE, NCT03038256: Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial |
|
|
| Recruiting | 2 | 244 | RoW | concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX | Peking University People's Hospital, Peking University Cancer Hospital & Institute, Beijing Friendship Hospital, Peking Union Medical College Hospital, Chinese PLA General Hospital, Shanghai Zhongshan Hospital, Fujian Medical University Union Hospital, Nanfang Hospital of Southern Medical University, Xijing Hospital, Hebei Medical University Fourth Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Affiliated Hospital of Hebei University | Rectal Cancer, Pathological Complete Response, Disease Free Survival | 04/23 | 06/25 | | |
NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer |
|
|
| Active, not recruiting | 2 | 150 | RoW | HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine | Shanghai Henlius Biotech | Gastric Cancer | 12/24 | 12/25 | | |
NCT05299476: CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA |
|
|
| Recruiting | 2 | 30 | RoW | CAPOX combined with bevacizumab and Tislelizumab | Chinese PLA General Hospital | Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5 | 12/24 | 06/25 | | |
NCT04156698: Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 51 | RoW | Docetaxel, Docetaxel (domestic), Cisplatin, chemotherapy drug, Capecitabine, Camrelizumab, Anti-PD-1 Antibody (Jiangsu Hengrui) | Eye & ENT Hospital of Fudan University | Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy | 04/23 | 01/26 | | |
MASTERPLAN, NCT04089150: MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease |
|
|
| Recruiting | 2 | 120 | RoW | Stereotactic Radiotherapy (SBRT), SBRT, Stereotactic Body Radiotherapy, mFOLFIRINOX, modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil (5-FU), Gemcitabine + Nab-paclitaxel, Gemcitabine + Abraxane, Gemcitabine + Capecitabine, GemCap, Pancreatoduodenectomy (Whipple procedure), Whipple | Australasian Gastro-Intestinal Trials Group, Trans Tasman Radiation Oncology Group, Australian Government Department of Health and Ageing | Pancreatic Cancer | 05/23 | 08/23 | | |
| Recruiting | 2 | 319 | RoW | SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi | Fudan University | Breast Cancer, Metastatic Cancer | 05/23 | 04/25 | | |
NOAHS-ARC, NCT04864067: No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 73 | RoW | Oxaliplatin, All Brands, 5-Fluoracil, Leucovorin, Capecitabine, 5x5 Gy, Quality of Life Questionnaires, DRE/ Endoscopy | Servicio de Salud Metropolitano Sur Oriente | Rectal Cancer | 12/24 | 05/25 | | |
NCT05335460: To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer |
|
|
| Not yet recruiting | 2 | 36 | NA | Envafolimab, XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w) | Fujian Cancer Hospital | Colon Cancer | 05/23 | 05/24 | | |
NCT04661150: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction |
|
|
| Active, not recruiting | 2 | 41 | RoW | Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Capecitabine, Oxaliplatin | Hoffmann-La Roche | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/23 | 08/26 | | |
ELECLA, NCT04188158: Analysis of the Effectiveness of Neoadjuvant Chemotherapy in the Treatment of Colon Cancer Locally Advanced |
|
|
| Recruiting | 2 | 238 | Europe | CAPECITABINE AND OXALIPLATIN | Universidad de León | Locally Advanced Colon Cancer | 05/23 | 03/24 | | |
| Recruiting | 2 | 53 | RoW | Tislelizumab, Oxaliplatin, S-1, Capecitabine | Sun Yat-sen University | Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach | 11/24 | 11/27 | | |
ChiCTR2100054759: Efficacy of Pyrotinib combined with trastuzumab and chemotherapy in patients with advanced her-2 positive metastatic breast cancer with or without brain metastasis |
|
|
| Recruiting | 2 | 55 | | Pyrotinib 400mg po qd/q21d + trastuzumab First dose 8mg/kg, followed by 6mg/kg ivgtt d1/q21d + any of the following chemotherapy drugs (capecitabine 1000/m2 po bid d1-14/q21d, Gemcitabine 1000mg/m2 ivgtt d1/q21d, Vinporibine 25mg/m2 ivgtt d1, 8/q21d or 80mg/m2 po d1, 8/q21d, docetaxel 75mg/m2 ivgtt d1/q21d, etc.) | Department of Breast Medicine, Cancer Hospital, Chinese Academy of Medical Sciences; Department of Breast Medicine, Cancer Hospital, Chinese Academy of Medical Sciences, fund assistance | breast cancer | | | | |
PICTURE, NCT04001621: Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer |
|
|
| Active, not recruiting | 2 | 100 | RoW | Pyrotinib combined with capecitabine | Fudan University | Metastatic Breast Cancer | 05/23 | 12/23 | | |
REVOLUTION, NCT04310176: Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 200 | Europe | Bevacizumab, mFOLFOX6 regimen, mOXXEL regimen, Valproic acid, Capecitabine, 5-fluorouracil | National Cancer Institute, Naples | Ras-mutated Metastatic Colorectal Cancer | 12/23 | 11/24 | | |
NCT04220528: Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC |
|
|
| Recruiting | 2 | 129 | RoW | Capecitabine/Tiggio, Radiation | Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/23 | 12/23 | | |
NCT04319471: Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 70 | RoW | Capecitabine/S-1, Maintenance chemotherapy, Chemotherapy, Head and neck radiotherapy, Local Consolidative Therapy | Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/23 | 06/23 | | |
NCT04543695: A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 2 | 255 | RoW | Concurrent Chemoradiotherapy, XELOX, CAOPX, mFOLFOX, TME | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Jilin Provincial Tumor Hospital, Cancer Hospital of Guizhou Province, Xijing Hospital | Rectal Cancer | 07/22 | 06/25 | | |
NCT04443348: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) |
|
|
| Recruiting | 2 | 120 | US | Radiation Therapy Boost, Pembrolizumab, Keytruda®., Paclitaxel, Taxol, Carboplatin, Paraplatin, Cyclophosphamide, Cytophosphane, Doxorubicin, Adriamycin, Capecitabine | Laura M. Spring, MD, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation, Translational Breast Cancer Research Consortium | Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s) | 06/24 | 12/24 | | |
NCT04720131: Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. |
|
|
| Completed | 2 | 28 | RoW | Camrelizumab, apatinib, Capecitabine | Beijing Friendship Hospital | Biliary Tract Cancer, Anti-PD-1 Therapy, Targeted Molecular Therapy, Capecitabine | 04/23 | 05/23 | | |
NCT05747326: Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | oral vinorelbine and capecitabine, metronomic agents (vinorelbine and capecitabine ) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Breast Cancer | 06/23 | 06/23 | | |
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 200 | RoW | Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV | Seoul National University Hospital | Pancreatic Cancer | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 122 | Europe | Eribulin Mesylate, Eribulin, Capecitabine | Consorzio Oncotech, EISAI S.r.l. | Metastatic Breast Cancer | 07/23 | 07/23 | | |
REPROGRAM-01, NCT04534218: Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 49 | Europe | Regorafenib, Stivarga, Cyclophosphamide, Endoxan, Capecitabine, Xeloda, Aspirin, Kardegic | Centre Hospitalier Universitaire de Besancon, Bayer | Colo-rectal Cancer, Metastatic Cancer | 12/23 | 12/23 | | |
MK-7119-001, NCT04721977: A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma |
|
|
| Active, not recruiting | 2 | 66 | Japan, RoW | Tucatinib, MK-7119, Tukysa, Trastuzumab, Herceptin, Herceptin Hylecta, Capecitabine, Xeloda | Pfizer | Breast Cancer | 07/23 | 12/28 | | |
ChiCTR2100048743: A randomized, open, multicenter phase II study of efficacy and safety comparing XELOX and a PD-1 inhibitor and a bevacizumab biosimilar drug (DAITON）with XELOX and a bevacizumab biosimilar drug (DAITON）in the first-line treatment of RAS mutated pMMR /MSS advanced colorectal cancer patients |
|
|
| Not yet recruiting | 2 | 120 | | XELOX combined with PD-1 inhibitor and bevacizumab biosimilar ;XELOX in combination with bevacizumab biosimilar | the First Medical Center of PLA General Hospital; PLA General Hospital, N/A | First-line treatment of RAS mutated PMMR /MSS advanced colorectal cancer | | | | |
ChiCTR2000035113: Phase II single arm clinical study of sintilimab combined with capecitabine in the treatment of platinum resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal adenocarcinoma |
|
|
| Not yet recruiting | 2 | 29 | | sintilimab combined with capecitabine | Mianyang Central Hospital; Mianyang Central Hospital, self-finance | Ovarian cancer, tubal cancer and primary peritoneal adenocarcinoma | | | | |
| Not yet recruiting | 2 | 48 | NA | Dalpiciclib+ letrozole +capecitabine | Fujian Medical University Union Hospital | Advanced Breast Cancer | 08/23 | 08/24 | | |
2018-000406-36: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE) |
|
|
| Not yet recruiting | 2 | 240 | Europe | nivolumab, ipilimumab, CISPLATIN, CAPECITABINE, Fluorouracil, EPIRUBICIN, Oxaliplatin, LEUCOVORIN, Docetaxel, L01XC11, Concentrate for solution for infusion, Film-coated tablet, Opdivo, Yervoy | European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for the Research and Treatment of Cancer, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION | Gastric, lower esophageal or GE-junction adenocarcinoma, Stomach cancer and cancer of the lower part of the esophageus, Diseases [C] - Cancer [C04] | | | | |
NCT05546411: A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer |
|
|
| Terminated | 2 | 8 | US | mFOLFIRINOX, 5-Fluorouracil (5-FU), Adrucil, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Camptothecin-11, CPT-1, Leucovorin, Calcium Leucovorin, Citrovorum Factor, Folinic Acid, NIS793, Chemoradiation, Surgery | Kimberly Perez, MD, Novartis | Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma | 08/23 | 10/23 | | |
MSCRT, ChiCTR1800016916: Preoperative Modified Short-Course Chemoradiotherapy in Middle-lower Locally Advanced Rectal Cancer: An Open-Label, Randomized, Parallel Controlled, Phase II trial |
|
|
| Not yet recruiting | 2 | 132 | | patients receive 1cycle of XELOX before concurrent capecitabine-based modified short-course radiotherapy, and after msCRT, another 3 cycles of XELOX as neoadjuvant chemotherapy would be given before TME surgery. ;concurrent capecitabine-based long-course radiotherapy, TME surgery and 4 cycles of XELOX as adjuvant chemotherapy. | Affiliated Hospital of Guangdong Medical University; Level of the institution：, IIS | Middle-lower Locally Advanced Rectal Cancer | | | | |
NCT04681911: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 71 | RoW | Inetetamab, Pyrotinib, Capecitabine, xeloda or other names, Gemcitabine, Gemzar or other names, Vinorelbine, Navelbine or other names, Carboplatin, Paraplatin or other names, Albumin paclitaxel, Abraxane or other names, Eribulin, Halaven | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 09/23 | 09/24 | | |
NCT05566743: A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas |
|
|
| Recruiting | 2 | 40 | RoW | Capecitabine, Xeloda, follow up | Menoufia University | Cancer of Pancreas | 09/23 | 09/24 | | |
NCT05549466: Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC |
|
|
| Recruiting | 2 | 84 | RoW | Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Apatinib, Camrelizumab, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel), Chemotherapy (gemcitabine/ capecitabine/ docetaxel) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 09/23 | 09/25 | | |
| Completed | 2 | 40 | Europe | Capecitabine, Cyclophosphamide | Vastra Gotaland Region | Breast Cancer Metastatic, Chemotherapy Effect | 10/23 | 10/23 | | |
NCT05042791: A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases |
|
|
| Recruiting | 2 | 362 | RoW | radiation combined with pyrotinib and capecitabine | Jiangxi Provincial Cancer Hospital | HER2-positive Metastatic Breast Cancer | 09/25 | 09/25 | | |
NCT05536102: The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) |
|
|
| Recruiting | 2 | 38 | RoW | PLD, Pegylated Liposomal Doxorubicin, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Tislelizumab, BGB-A317 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Gastric Cancer | 09/23 | 09/27 | | |
IMPROVE-IT, NCT03748680: IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer |
|
|
| Recruiting | 2 | 64 | Europe | Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule | Karen-Lise Garm Spindler | Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy, Progression Free Survival | 10/23 | 10/25 | | |
| Recruiting | 2 | 74 | Europe | Fluorouracil, Calcium folinate, Oxaliplatin, Bevacizumab, Capecitabine, Tocotrienol, Placebo | Vejle Hospital | Colorectal Cancer Metastatic | 10/24 | 10/24 | | |
TORCH, NCT04518280: Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 130 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, Oxaliplatin, Short-course radiotherapy | Fudan University | Locally Advanced Rectal Cancer | 10/23 | 12/25 | | |
NCT04390945: Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer |
|
|
| Recruiting | 2 | 62 | RoW | Camrelizumab, Capecitabine, concurrent radiotherapy | The First Affiliated Hospital of Henan University of Science and Technology | Esophageal Cancer | 10/23 | 08/24 | | |
N-PRC, NCT05576480: SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 55 | NA | Short-course radiotherapy, Penpulimab, PD-1 monoclonal antibody, CAPEOX, Capecitabine and oxaliplatin, TME surgery | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rectal Cancer, Locally Advanced | 10/23 | 12/26 | | |
NCT06284746: Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 80 | RoW | Tirolizumab+SOX/XELOX, SOX/XELOX | Lin Chen | Locally Advanced Gastric Carcinoma, HER2 Negative, Efficacy, Safety | 04/25 | 07/25 | | |
NCT03872388: Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy |
|
|
| Completed | 2 | 6 | US | Atorvastatin, Capecitabine, Ro 09-1978/000, Xeloda | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma | 10/23 | 10/23 | | |
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) |
|
|
| Terminated | 2 | 29 | RoW | Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine | Hoffmann-La Roche | Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 11/23 | 11/23 | | |
OPRA, NCT02008656: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management |
|
|
| Active, not recruiting | 2 | 358 | US | Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin, Capecitabine (Xeloda®), intensity modulated radiotherapy (IMRT), Quality of Life Questionnaires, DRE-Endoscopy | Memorial Sloan Kettering Cancer Center, Colon and Rectal Surgery Inc., The Cleveland Clinic, John Muir Health, Oregon Health and Science University, St. Joseph Hospital of Orange, University of California, Irvine, University of California, San Francisco, University of Chicago, University of South Florida, University of Vermont, University of Washington, Medstar Health Research Institute, Washington University School of Medicine, Creighton University Medical Center, The Methodist Hospital Research Institute, University of Rochester, University of Virginia, St. Paul's Hospital, St. Joseph, Florida, Cleveland Clinic Florida, University of Colorado, Denver, University of Michigan | Rectal Cancer | 11/24 | 11/24 | | |
NCT03703427: Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy |
|
|
| Not yet recruiting | 2 | 200 | RoW | Capecitabine, Oral, 500 Mg, Vinorelbine Tartrate Oral | Zhiyong Yu | Pathologic Residual Cancer Cells | 11/23 | 11/25 | | |
BreastImmune03, NCT03818685: Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease |
|
|
| Active, not recruiting | 2 | 95 | Europe | Nivolumab, Ipilimumab, Capecitabine | Centre Leon Berard | Breast Cancer, Triple Negative Breast Neoplasms | 03/24 | 05/24 | | |
NCT05641246: Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine |
|
|
| Completed | 2 | 86 | RoW | (CARBAMIDE®), Urea-based cream, (VOLTAREN®) Emulgel 1%, Diclofenac Sodium | German University in Cairo, Cairo University | Hand and Foot Syndrome | 11/23 | 12/23 | | |
NCT05255523: Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer |
|
|
| Not yet recruiting | 2 | 60 | NA | pyrotinib, capecitabine | Fujian Medical University Union Hospital | Advanced Breast Cancer | 11/23 | 12/24 | | |
